LexaGene Holdings Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John F. Regan
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 500 Cummings Center Beverly MA United States of America 01915
- CIK
- 0001450416
- Website
- lexagene.com
- Similar Companies
- Business
- LexaGene Holdings Inc. develops and commercializes automated pathogen detection systems for molecular diagnostics. The company offers the MiQLab system, an open-access PCR-based platform for on-site testing that screens up to 24 targets simultaneously with results in under two hours; MiQLab Bacterial and AMR V2 test panels for diagnosing infections in veterinary applications such as urinary tract, skin, wound, and ear conditions; MiQLab Pneumonia Panel for respiratory illness detection in animals; and related assay panels and sample preparation cartridges targeting pathogens in veterinary diagnostics, food safety, water quality, biopharmaceutical manufacturing, clinical research, agricultural testing, and biodefense markets. Founded in 2007 and headquartered in Beverly, Massachusetts, LexaGene primarily serves veterinary hospitals, reference laboratories, contract manufacturers, and open-access life sciences sectors across the United States. In February 2023, the company filed for Chapter 7 bankruptcy liquidation in the U.S. Bankruptcy Court for the District of Massachusetts after ceasing operations, laying off staff, and failing to secure funding amid challenging market conditions, lengthy biopharma sales cycles, and limited technology adoption, resulting in a court-appointed trustee to oversee asset distribution.
LexaGene Holdings announces MiQLab Systems sale to veterinary hospital in Wisconsin
LexaGene reveals MiQLab Systems sale to large US veterinary corporation
LexaGene's MiQLab system successfully detects biohazard agents in US Army R&D test
LexaGene unveils advancements to its sample preparation cartridge for veterinary market
LexaGene Holdings closes second tranche of $6.5M Meridian LGH investment
LexaGene says Meridian LGH agrees to make an investment totaling C$6,475,000 in the company
LexaGene Holdings kicks off the year with additional sales of its flagship MiQLab Systems
LexaGene closes multiple MiQLab sales as it makes good progress in sales cycle
LexaGene says Dr Jane Sykes, executive director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University of California, Davis has joined its board
LexaGene Holdings announces expansion of biopharma contamination panel by adding biothreat test to its MiQLab system
LexaGene awarded 2021 Biotech Breakthrough Molecular Diagnostics Solutions of the Year
LexaGene finalizes design of MiQLab pneumonia panel
LexaGene Holdings completes first stage of US Army DEVCOM agreement for developing biothreat defense, preparing for second stage in Maryland
LexaGene selected as a Best in Show Spotlight company for the 47th Annual Petcare Innovation Summit
LexaGene completes analytical studies for FDA EUA application for coronavirus (COVID-19) diagnostics
LexaGene completes analytical studies for FDA EUA application for COVID-19 diagnostics
LexaGene says its largest study validates accuracy of its veterinary test panel
LexaGene's Largest Study Validates Accuracy of its Veterinary Test Panel
LexaGene to Webcast Live at VirtualInvestorConferences.com October 7th
LexaGene to expand its brand awareness at three investor relations conferences in October